in pediatric type 2 diabetes, S219
in pregnancy, S236
to reduce ASCVD risk factors, S151
linagliptin, S133, S137, S159, S161, S167
lipase inhibitors, S117
lipid management, S151–S155
lipid profiles, S151
linagliptin, S24, S54, S116, S118, S133, S137, S140, S160, S165, S166, S167, S180, S181, S211, S222
lispro, S138, S139, S201
lixisenatide, S33, S137, S138, S140, S160, S166, S167
long-acting insulin analog, in type 1 diabetes, S126, S128–S130, S135, S138, S139, S201, S202, S212, S214, S249
Look AHEAD trial, S116
loss of protective sensation, S188, S191
lovastatin, S152
macular edema, diabetic, S186
maternal history, in screening children/adolescents, S23
maturity-onset diabetes of the young (MODY), S18, S28–S29, S208, S219
meal planning, S74–S75
medical devices, for weight loss, S119
medical evaluation, S5, S46–S59
autoimmune diseases, S53
cancer, S53
cognitive impairment/dementia, S53–S54
comprehensive, S48–S51
fractures, S55
hepatitis C infection, S54–S55
immunizations, S48, S50–S54
low testosterone in men, S55–S56
nonalcoholic fatty liver disease, S54, S55, S56
obstructive sleep apnea, S56
pancreatitis, S55
periodontal disease, S56
recommendations, S48
medical nutrition therapy, S62–S67
alcohol, S67
carbohydrates, S65–S66
eating patterns and meal planning, S64–S65
fats, S66–S67
goals of, S64
in hospitalized patients, S248
micronutrients and supplements, S67
protein, S66
recommendations, S63
sodium, S67
weight management, S64
medications
considerations in pregnancy, S239–S240
cost considerations, S4, S10
in diabetes screening, S26
glucose-lowering, impact on weight, S116
for weight loss, S116–S119
Mediterranean diet, S151
meglitinides, S51, S137
mental health referrals, S72, S73
mental illness, serious, S74
metabolic surgery, S119–S121, S221–S222
metoclopramide, S190
metoprolol, S190
micronutrients, S67
microvascular complications, S69–S70
A1C and, S87–S88
in pediatric type 1 diabetes, S217–S218
midodrine, S190
miglitol, S137
migrant farmworkers, S12
mineralocorticoid receptor antagonist therapy, S150–S151, S181
monogenic diabetes syndromes, S17, S28–S30
multiple daily injections (MDI), S99
myasthenia gravis, S53
naltrexone/bupropion ER, S116, S117
nateglinide, S42, S137
National Diabetes Data Group, S33
National Diabetes Prevention Program, S41
National Health and Nutrition Examination Survey (NHANES), S9, S19, S55, S219
neonatal diabetes, S17, S28
neurology, in type 1 diabetes, S209, S217
nephropathy
in pediatric type 1 diabetes, S209, S217
in pediatric type 2 diabetes, S210, S222
neurocognitive function, S196
neurologist, referral to, S182
neuropathy
in pediatric type 1 diabetes, S209, S217
in pediatric type 2 diabetes, S210, S222
new-onset diabetes after transplantation (NODAT), S27
niacin + statin therapy, S154–S155
nonalcoholic fatty liver disease (NAFLD), S5, S54, S55, S56
in pediatric type 1 diabetes, S210, S223
nonalcoholic steatohepatitis (NASH), S5, S54
noninsulin treatments
in type 1 diabetes, S127, S130
noninsulin-dependent diabetes, see type 2 diabetes.
nonnutritive sweeteners, S67
NPV insulin, S126, S127, S128–S130, S133, S135, S138, S139, S140, S201, S247, S249
nucleoside reverse transcriptase inhibitors A1C and, S20
nursing homes, S203–S204
nutrition therapy
diabetes, S54
for diabetes prevention, S40–S41
with diabetic kidney disease, S179
in pediatric type 1 diabetes, S211
obesity, S5, S113–S124
assessment, S113–S114
diet, physical activity, and behavioral therapy, S114–S119
medical devices for weight loss, S119
metabolic surgery, S119–S121
pharmacotherapy, S116–S119
screening asymptomatic children/adolescents, S23
obstructive sleep apnea, S56
in pediatric type 2 diabetes, S210
ODYSSEY OUTCOMES trial, S153
older adults, S7, S195–S207
end-of-life care, S204
hypoglycemia, S196–S197
lifestyle management, S198–S199
neurocognitive function, S196
pharmacologic therapy, S199–S203
in skilled nursing facilities and nursing homes, S203–S204
treatment goals, S197–S198
with type 1 diabetes, S203
one-step strategy, for GDM, S32
opioid antagonist/antidepressant combination, S117
ophthalmologist, referral to, S186, S187, S224
oral agents, BGM for patients using, S99
oral glucose tolerance test (OGTT), S18, S19, S23, S26, S27, S28, S29, S31, S32, S33, S36
organ transplantation, posttransplantation diabetes mellitus, S17, S27–S28
orlistat, S116, S117
orthostatic hypotension, S190
overweight, screening asymptomatic children/adolescents, S23
oxygen, glucose monitors and, S100
P2Y12 receptor antagonists, S155, S157
palliative care, S204
pancreas transplantation, S130–S131
pancreatectomy, S30
pancreatitis, S55
pancreovipric diabetes, S30
patient-centered care goals, S43
patient-centered collaborative care, S46–S48
pens, insulin, S102–S103
periodontal disease, S26, S56
perioperative care, S249
peripheral arterial disease, S191
peripheral neuropathy, S70
peripheral neuropathy, diabetic, S188
pernicious anemia, S53
pharmacologic approaches, see also specific medications, medication classes, S6, S125–S143
for adults with type 1 diabetes, S125–S130
for adults with type 2 diabetes, S131–S141
for hypertension, S149–S151
in older adults, S199–S203
for pediatric type 2 diabetes, S220–S221
in prediabetes, S42
for weight loss, S116–S119
phentermine, S116, S117
phentermine/topiramate ER, S116, S117
phosphodiesterase type 5 inhibitors, S190
photocoagulation surgery, S187
physical activity, S41, S67–S70
for diabetes prevention, S41, S114–S115
for diabetes treatment, S114–S115
frequency and type, S67–S68
glycemic control and, S68
with microvascular complications, S68–S70
in pediatric type 1 diabetes, S211
pre-exercise evaluation, S68
pioglitazone, S55, S133, S137, S154
PIONEER-6 trial, S160–S161, S165
pitavastatin, S152
Plenity, S119
pneumococcal pneumonia vaccines, S51, S52
poly cystic ovarian syndrome, S210
population health, S4, S8–S16
tricyclic antidepressants, S190  
TWILIGHT trial, S157  
two-hour plasma glucose (2-h PG) test, S18, S19  
two-step strategy, for GDM, S32–S33  
type 1 diabetes, S4  
A1C and cardiovascular disease outcomes in, S88–S89  
initial therapy, S132  
in children/adolescents, S211–S218  
classification, S17–S18  
diagnosis, S4, S20–S22  
examples of subcutaneous insulin regimens, S128–S130  
idiopathic, 21  
immuno-mediated, 21  
insulin therapy in hospitalized patients, S247  
noninsulin treatments, S127, S130  
in older adults, S203  
pharmacologic treatment in adults, S125–S130  
pregnancy in women with preexisting, S239  
retinopathy in, S186  
screening, S4, S21–S22  
staging, S18  
surgical treatment, S130–S131  
type 2 diabetes, S4  
A1C and cardiovascular disease outcomes in, S88–S89  
in children/adolescents, S218–S224  
classification, S4, S17–S18  
combination therapy, S132, S135  
drug-specific and patient factors to consider, S133  
vertebral surgery, S119  
vascular disease, prevention of, in prediabetes, S42–S43  
venaloxine, S190  
VERIFY trial, S135  
vildagliptin, S135  
weight loss surgery. see metabolic surgery. weight loss/management  
in diabetes prevention, S40, S41, S42, S43, S113–S124  
in type 2 diabetes, S5, S60–S82  
whites, non-Hispanic, A1C differences in, S84–S84  
zoster vaccine, S53